Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + serplulimab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
- Pemetrexed is an antifolate chemotherapy agent used primarily for non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. It inhibits folate-dependent enzymes involved in nucleotide synthesis, thereby inhibiting tumor cell replication. - Serplulimab is a novel anti-PD-1 monoclonal antibody that blocks the programmed death-1 (PD-1) immune checkpoint receptor, enhancing T-cell mediated antitumor immune response. - The combination of pemetrexed with serplulimab has been studied as a first-line treatment for advanced non-squamous NSCLC without driver mutations. Clinical trials demonstrated that adding serplulimab to chemotherapy including pemetrexed significantly improves progression-free survival and overall survival compared to chemotherapy alone. - Developed by Henlius, this combination offers a new immunotherapy plus chemotherapy option for advanced NSCLC patients, especially those negative for driver gene mutations.
- Brand names
- HANSIZHUANG (serplulimab)
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pemetrexed + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + serplulimab.